Tigecycline: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
+ | == Background == |
||
+ | |||
*Glycylcycline antibiotic |
*Glycylcycline antibiotic |
||
− | == |
+ | ===Spectrum of Activity=== |
*Related to [[tetracycline]] and [[doxycycline]], with expanded coverage to include [[streptococci]] and [[Enterobacteriaceae]], but without coverage for unusual [[Gram-negative bacteria]] or [[Chlamydia trachomatis]] |
*Related to [[tetracycline]] and [[doxycycline]], with expanded coverage to include [[streptococci]] and [[Enterobacteriaceae]], but without coverage for unusual [[Gram-negative bacteria]] or [[Chlamydia trachomatis]] |
||
*Does cover [[Acinetobacter]] and [[Stenotrophomonas]] |
*Does cover [[Acinetobacter]] and [[Stenotrophomonas]] |
||
+ | |||
+ | === Pharmacokinetics and Pharmacodynamics === |
||
+ | |||
+ | * Rapidly concentrates in tissue, but poor concentration in urine and lung tissue |
||
+ | |||
+ | == Dosing == |
||
+ | |||
+ | * High dosing may be useful in HAP/VAP with 100 mg IV q12h |
||
+ | |||
+ | == Safety == |
||
+ | |||
+ | * Black box warning for increased all-cause mortality (4 vs 3%), likely driven by standard dosing tigecycline in VAP |
||
[[Category:Glycylcyclines]] |
[[Category:Glycylcyclines]] |
Revision as of 09:29, 3 February 2021
Background
- Glycylcycline antibiotic
Spectrum of Activity
- Related to tetracycline and doxycycline, with expanded coverage to include streptococci and Enterobacteriaceae, but without coverage for unusual Gram-negative bacteria or Chlamydia trachomatis
- Does cover Acinetobacter and Stenotrophomonas
Pharmacokinetics and Pharmacodynamics
- Rapidly concentrates in tissue, but poor concentration in urine and lung tissue
Dosing
- High dosing may be useful in HAP/VAP with 100 mg IV q12h
Safety
- Black box warning for increased all-cause mortality (4 vs 3%), likely driven by standard dosing tigecycline in VAP